mitiglinide

a rapid and short-acting hypoglycemic agent; acts on sulfonylurea receptor closing KATP channels; considered one of the glinides-an imprecise grouping; structure given in first source

Also Known As:

2-benzyl-3-(hexahydro-2-isoindolinylcarbonyl)propionate; KAD 1229; KAD-1229; S21403; calcium 2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate; miti-glinide; 2H-Isoindole-2-butanoic acid, octahydro-gamma-oxo-alpha-(phenylmethyl)-, calcium salt, (2(S)-cis)-

Networked: 62 relevant articles (12 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoindoles: 18
      - mitiglinide: 62

Experts

1.	Ojima, Kazuma: 5 articles (12/2017 - 01/2002)
2.	Kaku, Kohei: 4 articles (06/2014 - 01/2009)
3.	Ono, Yuri: 3 articles (09/2014 - 03/2013)
4.	Tanaka, Yasushi: 3 articles (12/2013 - 02/2006)
5.	Kojima, Masami: 3 articles (02/2006 - 01/2002)
6.	Arao, Tadashi: 2 articles (01/2018 - 01/2017)
7.	Okada, Yosuke: 2 articles (01/2018 - 01/2017)
8.	Tanaka, Yoshiya: 2 articles (01/2018 - 01/2017)
9.	Torimoto, Keiichi: 2 articles (01/2018 - 01/2017)
10.	Akahane, Kenji: 2 articles (12/2017 - 07/2017)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 02/01/2012 - "This study was performed to examine the efficacy and safety of mitiglinide in type 2 diabetes patients (T2DM). " 11/01/2009 - "This study investigated the effects of mitiglinide in 16 patients with type 2 diabetes mellitus treated with 30 mg/day mitiglinide, divided into three doses given just before each meal, for approximately 12 months. " 11/01/2009 - "In this study, a urinary metabonomics method based on ultra-performance liquid chromatography-tandem mass spectrometry was developed to study the effect mechanism of mitiglinide on type 2 diabetes mellitus. " 10/01/2013 - "Mitiglinide for type 2 diabetes treatment." 06/29/2012 - "Mitiglinide is a short-acting insulinotropic agent used in type 2 diabetes treatment. "
2.	Hyperglycemia 10/01/2010 - "Mitiglinide is the third agent in the class of meglitinides that targets postprandial hyperglycemia. " 10/01/2010 - "Because of a more intensive dosing regimen, potential cost, and lack of studies assessing the clinical impact of mitiglinide therapy on oxidative stress and inflammatory markers secondary to postprandial hyperglycemia, we cannot recommend this therapy over currently approved therapies." 06/29/2012 - "Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide." 10/01/2010 - "Mitiglinide has been shown through small clinical studies (N <400) to modestly decrease hemoglobin A(1c), postprandial hyperglycemia, and oxidative stress and inflammatory markers associated with postprandial hyperglycemia. " 10/01/2004 - "In clinical trials, treatment with mitiglinide provided lasting improvement of postprandial hyperglycemia in Type 2 diabetic patients and decreased the fasting plasma glucose levels and HbA(1C) values. "
3.	Hypoglycemia (Reactive Hypoglycemia) 10/01/2010 - "Overall, mitiglinide is well tolerated, with the most common adverse effect being hypoglycemia. " 01/01/2010 - "Mitiglinide can be safely used for diabetic patients on HD, if careful attention is paid to hypoglycemia." 10/01/2004 - "The incidence of adverse events related to mitiglinide were nearly equivalent to placebo; in particular there was no difference with the frequency of hypoglycemia. " 02/01/2001 - "In this model, KAD-1229 reduced the increase in plasma glucose level without producing hypoglycemia. " 10/01/2004 - "The results from these studies indicated that mitiglinide could be expected to possess good therapeutic features of being effective in reducing postprandial glucose excursions in the early stage of Type 2 diabetes and less incidence of events suggestive of hypoglycemia."
4.	Diabetes Mellitus 01/01/2017 - "The results of our experiment suggested that the model can be used reasonably to predict the relationship between PK and PD in mitiglinide, which could be used in diabetes mellitus dosage control in clinical trials and other fields." 06/01/2020 - "Mitiglinide (MTG) is one of meglitinides group which are used for treatment of type two diabetes mellitus. " 06/05/2011 - " In the present study, we compared the efficacy of two options in type 2 diabetes mellitus patients whose blood glucose had not been well controlled with mitiglinide (30 mg/day) alone. " 06/05/2011 - "Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus." 08/01/2018 - "Gastroretentive Microsponge as a Promising Tool for Prolonging the Release of Mitiglinide Calcium in Type-2 Diabetes Mellitus: Optimization and Pharmacokinetics Study."
5.	Glucose Intolerance 02/01/2005 - "[Effects of mitiglinide in treatment of impaired glucose tolerance]." 01/01/1995 - "NIDDM rats that were given a neonatal injection of 60 mg/kg streptozotocin showed a dose-dependent but attenuated response to oral administration of KAD-1229 and gliclazide, and their impaired glucose tolerance was improved but not normalized. "

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Insulin (Novolin)
3.	voglibose (Basen)
4.	Insulin Glargine (Lantus)
5.	Insulin Aspart (NovoLog)
6.	Sitagliptin Phosphate (Januvia)
7.	Blood Glucose (Blood Sugar)
8.	Hypoglycemic Agents (Hypoglycemics)
9.	Metformin (Glucophage)
10.	repaglinide (Prandin)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Oral Administration